Centrum für Hämatologie und Onkologie Bethanien

Industry / private company


Location: Frankfurt/Main, Germany (DE) DE

ISNI: -

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients (2016) Rack B, Jueckstock J, Trapp E, Weissenbacher T, Alunni-Fabbroni M, Schramm A, Widschwendter P, et al. Journal article Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients (2016) Hein A, Gaß P, Walter CB, Taran FA, Hartkopf A, Overkamp F, Kolberg HC, et al. Journal article Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy (2015) Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching P, Pfitzner BM, Gerber B, et al. Journal article Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study (2015) Hein A, Lambrechts D, Von Minckwitz G, Haeberle L, Eidtmann H, Tesch H, Untch M, et al. Journal article Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study (2014) Fasching P, Fehm T, Kellner S, De Waal J, Rezal M, Baler B, Baake G, et al. Journal article Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial (2014) Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, et al. Journal article Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44) (2014) Gerber B, Von Minckwitz G, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, et al. Journal article Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro) (2014) Von Minckwitz G, Rezai M, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, et al. Journal article Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial (2010) Witzel I, Loibl S, Von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, et al. Journal article
‹ 1 ... 6 7 8 ›